Seeking Alpha
View as an RSS Feed

Spencer Osborne  

View Spencer Osborne's Articles BY TICKER:
  • Arena: Belviq Television Ads Resume After 1 Week Hiatus
    Tue, Feb. 24 ARNA 29 Comments

    Summary

    • Eisai identified low price and television ads as new strategy.
    • Televion ad numbers have declined throughout 2015.
    • Between February 16th and February 23rd there were no ads run.
  • Orexigen: Contrave Scripts Pass 9,000 - Closing In On Qsymia
    Mon, Feb. 23 OREX Comment!

    Summary

    • Contrave is now 18 weeks into launch and poised to catch Qsymia already.
    • Contrave new scripts tracking well, while refills could use improvement.
    • U.S sales tracking okay, but decision in Europe is the big catalyst for equity.
  • Arena: Belviq Sales Show Modest Gain - Time To Assess 2015 Expectations?
    Mon, Feb. 23 ARNA 45 Comments

    Summary

    • Belviq sales are up 2.54% week over week, less than what is needed.
    • Sales are not growing fast enough to offset a lower price point.
    • Investors may want to model expectations sooner rather than later.
  • Orexigen's Contrave Sales Recover - Investors Should Look To Europe
    Wed, Feb. 18 OREX 9 Comments

    Summary

    • Sales move up by 10% week over week.
    • Contrave continues to gain market share.
    • Investors will want to monitor Vivus news.
  • Arena's Belviq Scripts Spike - Maintaining This Trajectory Important
    Wed, Feb. 18 ARNA 48 Comments

    Summary

    • Script sales spike to highest levels.
    • Sales trajectory on track for the first time in 2015.
    • Investors should be happy with the spike, but aware that sales are still behind pace.
  • European Decision On Orexigen Gets Delayed Until March, But Approval Is Likely
    Mon, Feb. 9 OREX 10 Comments

    Summary

    • CHMP vote to approve was 31 in favor and 2 opposed.
    • European Commission will render final decision in March.
    • It was previously thought decision would come in February.
  • Vivus: Qsymia Sales Dip - Is A Lower Price Needed?
    Sun, Feb. 8 VVUS 38 Comments

    Summary

    • Qsymia sales dip 3.5%.
    • Qsymia now higher priced than Contrave or Belviq.
    • Qsymia sales have been very flat for 15 months.
  • Orexigen: Contrave Script Sales Dip. Why?
    Fri, Feb. 6 OREX 11 Comments

    Summary

    • Contrave sales were flat last week and dipped this week.
    • Competitor lowered price two weeks ago.
    • What can help Contrave win back scripts?
  • Arena Scripts Grow, But Pace Is Slower Than Needed
    Fri, Feb. 6 ARNA 45 Comments

    Summary

    • Scripts have been pretty flat for 20 weeks.
    • Sales growth at higher levels is needed ASAP.
    • Belviq sales were better than competitors, but still not where desired.
  • Arena's Partner May Need To Advertise More
    Wed, Feb. 4 ARNA 37 Comments

    Summary

    • About 50 Belviq ads run per day.
    • Prime Time ads slower than average.
    • Thus far in 2015, sales have not picked up as needed.
  • Arena's Belviq Approved In South Korea - Can It Change The Dynamics?
    Wed, Feb. 4 ARNA 30 Comments

    Summary

    • South Korean partner Ildong paid Arena a $3 million milestone.
    • South Korea has the best handle on obesity.
    • No news on a launch date or price point.
  • With Flat Qsymia Sales, Vivus May Shift Focus To Stendra/Spedra
    Tue, Feb. 3 VVUS 22 Comments

    Summary

    • Sales of Qsymia have remained in same channel for months.
    • Competitors have lower prices.
    • Company focus seems to be shifting to Stendra/Spedra.
  • Can Ford Rise 10% In The Next 6 Months?
    Mon, Feb. 2 F 19 Comments

    Summary

    • Equity is below $15, yet sales are anticipated to rise.
    • Ford typically shows early-year growth.
    • Overall auto sales not expected to peak until 2016 or 2017.
  • Orexigen: Contrave Scripts Slow Down - Competition Lowers Price
    Mon, Feb. 2 OREX 5 Comments

    Summary

    • Contrave's big pricing advantage is vanishing.
    • Contrave sales see modest gain, but not as good as competitors.
    • Contrave refill story taking shape.
  • Arena's Belviq Sales Need Better Pace
    Mon, Feb. 2 ARNA 39 Comments

    Summary

    • Sales pace is behind what is needed to deliver revenue that the Street will appreciate.
    • New lower price point is helping against competition.
    • Investors should be cautious.
  • Landstar Closes 2014 With Records
    Mon, Feb. 2 LSTR Comment!

    Summary

    • Revenue, profit, operating income and earnings all set records.
    • Average loads and revenue per load saw records in 2014.
    • Q4 revenue was $863 million and EPS was $0.86 per share.
  • Gallup Says Obesity Rates Climb Again - Can Anti-Obesity Companies Cash In?
    Wed, Jan. 28 ARNA 20 Comments

    Summary

    • Obesity rates climb again in 2014.
    • A shift in thoughts about obesity is needed.
    • Several companies offer potential solutions.
  • Arena - Flat Scripts Is Not A Good Start To 2015
    Tue, Jan. 27 ARNA 36 Comments

    Summary

    • Scripts were flat week over week.
    • New price point needs to deliver volume.
    • Excuses will not satisfy the street.
  • Contrave Scripts Continue Increases For Orexigen
    Tue, Jan. 27 OREX 12 Comments

    Summary

    • Script sales delivering impressive growth trajectory.
    • Contrave may close sales gap in a matter of a few months.
    • Contrave sales surpass 7,500.
  • Novo Nordisk Receives Positive Opinion In Europe On Obesity Treatment
    Fri, Jan. 23 NVO Comment!

    Summary

    • Saxenda already has FDA approval.
    • Saxenda joins Orexigen's Contrave as yet another possible new treatment in Europe.
    • Novo Nordisk has not launched Saxenda in the U.S. yet.
  • Arena's Sales Pace For Belviq - What Is Needed
    Wed, Jan. 21 ARNA 28 Comments

    Summary

    • First full week of sales sets the stage.
    • Lower price means more volume needed.
    • Watch the first 8 weeks of the year closely because the street is doing just that.
  • Orexigen Scripts Continue Impressive Track
    Wed, Jan. 21 OREX 9 Comments

    Summary

    • Contrave sales were up 41.24%.
    • Investors should start to watch refills.
    • Competitors' new pricing could impact trajectory.
  • Arena Announces Dilution - What Does It Mean?
    Wed, Jan. 21 ARNA 27 Comments

    Summary

    • Company announces intent to offer shares.
    • Dilution was a likely 2015 event by most estimates.
    • Size of dilution is 21 million shares.
  • Enteromedics Garners FDA Approval For Obesity Device: What's Next
    Fri, Jan. 16 ETRM 75 Comments

    Summary

    • Maestro device is pacemaker type device for obesity.
    • FDA approved device for people with BMI of 35 or more with co-morbid condition.
    • Device slated to cost about $15,000.
  • Vivus Gets New 10% Stakeholder: What To Watch For
    Mon, Jan. 12 VVUS 103 Comments

    Summary

    • North Tide becomes new 10% stakeholder in Vivus.
    • Multiple purchases show that North Tide Adding Shares.
    • Investors will want to watch closely.
  • A Deeper Look At Arena's Belviq Pricing
    Mon, Jan. 12 ARNA 27 Comments

    Summary

    • Lower price will drive new consumers and retain existing ones.
    • More volume needed to get similar revenue.
    • Build models and set expectations now, as it is to your advantage.
  • Orexigen's Contrave May Have Pricing Competition
    Mon, Jan. 12 OREX 15 Comments

    Summary

    • Orexigen's Contrave entered market in October as pricing leader.
    • Contrave sales have had the most impressive launch trajectory.
    • New pricing for Arena's Belviq may apply pressure.
  • Sales Of Arena's Belviq Close Out 2014 - What Will 2015 Bring?
    Fri, Jan. 9 ARNA 14 Comments

    Summary

    • The company should meet its guidance.
    • New price structure for Belviq gives investors a lot to consider.
    • First full week of 2015 script sales due out next week.
  • Arena Investors Should Watch New Pricing Of Belviq Closely
    Fri, Jan. 9 ARNA 37 Comments

    Summary

    • New Drug Price can spur sales, but revenue needs to be monitored.
    • FDA adverse events were released with no real red herrings.
    • Pipeline news is good, but company valuation is reliant upon Belviq sales in near term.
  • Arena Spikes On Pipeline News
    Wed, Jan. 7 ARNA 42 Comments

    Summary

    • Clinical Trial news highlights that Area is more than just Belviq.
    • Stock sees spike of over 30%.
    • Pipeline news should help stock create a new foundation.
  • Anticipated FDA Approval Eludes Enteromedics
    Mon, Jan. 5 ETRM 47 Comments

    Summary

    • Company was expecting FDA decision in 2014.
    • Investors' patience is being tested.
    • Enteromedics remains highly speculative.
  • Can High Priced Novo Nordisk Anti-Obesity Injection Make It?
    Dec. 29, 2014 NVO 10 Comments

    Summary

    • Analysts expect Saxenda injection to cost $25 per day.
    • Results seem to be in line with less expensive pills.
    • Saxenda to launch in 2015, website already launched.